# reload+after+2024-01-23 08:46:46.247285
address1§9390 Towne Centre Drive
address2§Suite 200
city§San Diego
state§CA
zip§92121
country§United States
phone§858 779 3100
website§https://poseida.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
fullTimeEmployees§327
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Mark J. Gergen J.D.', 'age': 60, 'title': 'Executive Chairman of the Board', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 920740, 'exercisedValue': 0, 'unexercisedValue': 817228}, {'maxAge': 1, 'name': 'Mr. Harry J. Leonhardt Esq., J.D.', 'age': 66, 'title': 'General Counsel, Chief Compliance Officer & Corporate Secretary', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 630233, 'exercisedValue': 0, 'unexercisedValue': 25579}, {'maxAge': 1, 'name': 'Mr. Brent  Warner', 'age': 39, 'title': 'President of Gene Therapy', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 835929, 'exercisedValue': 0, 'unexercisedValue': 151938}, {'maxAge': 1, 'name': 'Dr. Kristin  Yarema Ph.D.', 'age': 51, 'title': 'President & CEO', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Johanna M. Mylet CPA', 'age': 36, 'title': 'Chief Financial Officer', 'yearBorn': 1987, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Loren  Wagner', 'title': 'Senior Vice President of Global Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kristin  Martin', 'title': 'Chief People & Administration Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Sarah  Thailing', 'title': 'Senior Director of Corporate Communications & IR', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Devon J. Shedlock Ph.D.', 'title': 'Chief Scientific Officer of Cell Therapy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lisa  Portale', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.336
priceToSalesTrailing12Months§6.09195
currency§USD
dateShortInterest§1702598400
forwardEps§-1.57
pegRatio§-0.8
exchange§NMS
quoteType§EQUITY
shortName§Poseida Therapeutics, Inc.
longName§Poseida Therapeutics, Inc.
firstTradeDateEpochUtc§1594387800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§291e20e1-54d3-33de-96cd-b23bf8be3533
gmtOffSetMilliseconds§-18000000
targetHighPrice§20.0
targetLowPrice§10.0
targetMeanPrice§14.0
targetMedianPrice§12.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§3.216
grossMargins§-1.98702
ebitdaMargins§-2.63842
trailingPegRatio§None
